Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6

Journal of Virology

Volumn 78, Issue 16, 2004, Pages 8468-8476

  Peng, Shiwen ^a   Ji, Hongxiu ^a   Trimble, Cornelia ^a   He, Liangmei ^a   Tsai, Ya Chea ^a   Yeatermeyer, Jessica ^a   Boyd, David A K ^a   Hung, Chien Fu ^a   Wu, T C ^a,b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; CALRETICULIN PROTEIN E6 DNA VACCINE; CD8 ANTIGEN; DNA VACCINE; PLASMID DNA; PROTEIN E6; PROTEIN E7; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG TARGETING; EPITOPE MAPPING; GENE GUN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE RESPONSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; T LYMPHOCYTE ACTIVATION; UTERINE CERVIX CANCER; VACCINATION; VIRUS STRAIN; WART VIRUS; WILD TYPE;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; CALRETICULIN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; DRUG DESIGN; H-2 ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; MICE; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; VACCINATION; VACCINES, DNA; VIRAL VACCINES;

EID: 3543110741     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.16.8468-8476.2004     Document Type: Article

References (28)

1. Basu, S., and P. K. Srivastava. 1999. Calreticulin, a peptide-binding chaperone of the endoplasmic reticulum, elicits tumor- and peptide-specific immunity. J. Exp. Med. 189:797-802.
2. b binding and immunogenic peptides from human papilloma virus tumour antigens E6 and E7. Scand. J. Immunol. 42:317-323.
3. Chen, C. H., T. L. Wang, C. F. Hung, Y. Yang, R. A. Young, D. M. Pardoll, and T. C. Wu. 2000. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res. 60:1035-1042.
4. Cheng, W. F., C. F. Hung, C. Y. Chai, K. F. Hsu, L. He, M. Ling, and T. C. Wu. 2001. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. J. Clin. Investig. 108:669-678.
5. Condon, C., S. C. Watkins, C. M. Celluzzi, K. Thompson, and L. D. Falo, Jr. 1996. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2:1122-1128.
6. Conway, E. M., L. Liu, B. Nowakowski, M. Steiner-Mosonyi, S. P. Ribeiro, and M. Michalak. 1995. Heat shock-sensitive expression of calreticulin. In vitro and in vivo up-regulation. J. Biol. Chem. 270:17011-17016.
7. Donnelly, J. J., J. B. Ulmer, J. W. Shiver, and M. A. Liu. 1997. DNA vaccines. Annu. Rev. Immunol. 15:617-648.
8. Feltkamp, M. C., H. L. Smits, M. P. Vierboom, R. P. Minnaar, B. M. de Jongh, J. W. Drijfhout, J. ter Schegget, C. J. Melief, and W. M. Kast. 1993. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23:2242-2249.
9. b-restricted cytotoxic T cell epitope. J. Immunol. 155:5519-5526.
10. He, Z., A. P. Wlazlo, D. W. Kowalczyk, J. Cheng, Z. Q. Xiang, W. Giles-Davis, and H. C. Ertl. 2000. Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology 270:146-161.
11. Hung, C. F., and T. C. Wu. 2003. Improving DNA vaccine potency via modification of professional antigen presenting cells. Curr. Opin. Mol. Ther. 5:20-24.
12. Kim, J. W., C. F. Hung, J. Juang, L. He, T. W. Kim, D. K. Armstrong, S. I. Pai, P. J. Chen, C. T. Lin, and T. C. Wu. 2004. Comparison of HPV DNA vaccines employing intracellular targeting strategies. Gene Ther. 11:1011-1018.
13. Kim, T. W., J. H. Lee, C. F. Hung, S. Peng, R. Roden, M. C. Wang, R. Viscidi, Y. C. Tsai, L. He, P. J. Chen, D. A. K. Boyd, and T. C. Wu. 2004. Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus. J. Virol. 78:4638-4645.
14. Lin, C. T., C. F. Hung, J. Juang, L. He, K. Y. Lin, T. W. Kim, and T. C. Wu. 2003. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles. Mol. Ther. 8:559-566.
15. Lin, K.-Y., F. G. Guarnieri, K. F. Staveley-O'Carroll, H. I. Levitsky, T. August, D. M. Pardoll, and T.-C. Wu. 1996. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56:21-26.
16. Ling, M., M. Kanayama, R. Roden, and T. C. Wu. 2000. Preventive and therapeutic vaccines for human papillomavirus-associated cervical cancers. J. Biomed. Sci. 7:341-356.
17. Moniz, M., M. Ling, C. F. Hung, and T. C. Wu. 2003. HPV DNA vaccines. Front. Biosci. 8:D55-D68.
18. Nash, P. D., M. Opas, and M. Michalak. 1994. Calreticulin: not just another calcium-binding protein. Mol. Cell. Biochem. 135:71-78.
19. Pardoll, D. M., and A. M. Beckerleg. 1995. Exposing the immunology of naked DNA vaccines. Immunity 3:165-169.
20. Parker, K. C., M. A. Bednarek, and J. E. Coligan. 1994. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J. Immunol. 152:163-175.
21. + T cells after gene gun immunization. J. Exp. Med. 188:1075-1082.
22. Robinson, H. L., and C. A. Torres. 1997. DNA vaccines. Semin. Immunol. 9:271-283.
23. Sadasivan, B., P. J. Lehner, B. Ortmann, T. Spies, and P. Cresswell. 1996. Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. Immunity 5:103-114.
24. Shedlock, D. J., and D. B. Weiner. 2000. DNA vaccination: antigen presentation and the induction of immunity. J. Leukoc. Biol. 68:793-806.
25. Spee, P., and J. Neefjes. 1997. TAP-translocated peptides specifically bind proteins in the endoplasmic reticulum, including gp96, protein disulfide isomerase and calreticulin. Eur. J. Immunol. 27:2441-2449.
26. Walboomers, J. M., M. V. Jacobs, M. M. Manos, F. X. Bosch, J. A. Kummer, K. V. Shah, P. J. Snijders, J. Peto, C. J. Meijer, and N. Munoz. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189:12-19.
27. Wu, T.-C., F. G. Guarnieri, K. F. Staveley-O'Carroll, R. P. Viscidi, H. I. Levitsky, L. Hedrick, K. R. Cho, T. August, and D. M. Pardoll. 1995. Engineering an intracellular pathway for MHC class II presentation of HPV-16 E7. Proc. Natl. Acad. Sci. USA 92:11671-11675.
28. Zemmour, J., A. M. Little, D. J. Schendel, and P. Parham. 1992. The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon. J. Immunol. 148:1941-1948.